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Abstract
Introduction: Generally, squamous cell carcinoma carries a poor prognosis because of its tendency to local invasion and subsequent
metastasis, which is mediated by multiple factors and angiogenesis. Hepatocyte growth factor (HGF) is a potent mitogen for epithelial cells
and regulates cell proliferation and migration and survival tumour angiogenesis and invasiveness.
The aim of the study presented here was to determine the serum concentration of HGF in patients with oral squamous cell carcinoma
before and after initial treatment.
Material and methods: The investigation was carried out in a group of 10 men and 10 women who had been hospitalised at the Depart-
ment of Craniomaxillofacial Surgery because of oral squamous cell carcinoma. Blood samples were collected before and four weeks after
initial treatment. Concentrations of HGF were determined in all blood serum samples.
Results: In patients with oral squamous cell carcinoma daily oscillations of the mean values of HGF were significantly higher than those in
healthy volunteers (p < 0.001). Serum concentrations of HGF were significantly higher in those patients who had undergone tumour and
regional lymph node resection. Serum HGF levels correlated positively with primary tumour stage. In our study no significant association
was observed between HGF levels and histological differentiation, but the daily oscillation of HGF was higher in those with G3 than in
those with G2 and G1 status.
Conclusions: Our data showed that the changes can be important pathogenic elements involved in the progression of oral squamous cell
carcinoma and may be a useful marker for clinical monitoring. (Pol J Endocrinol 2008; 59 (6): 467–470)
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Streszczenie
Wstęp: Rak płaskonabłonkowy błony śluzowej jamy ustnej charakteryzuje się wysokim stopniem inwazji miejscowej i wysoką częstotli-
wością przerzutów do szyjnych węzłów chłonnych. Proces inwazji i tworzenia przerzutu składa się z wielu połączonych wzajemnych
relacji gospodarza i guza nowotworowego. Hepatocytowy czynnik wzrostu (HGF) jest potencjalnym mitogenem dla komórek nabłonko-
wych, który reguluje proliferację, ich ruchliwość, przeżycie, angiogenezę guza i inwazyjność.
Celem pracy była ocena stężenia HGF u chorych z rakiem płaskonabłonkowym jamy ustnej przed i po leczeniu chirurgicznym.
Materiał i metody: Badania przeprowadzono u 20 pacjentów, 10 mężczyzn i 10 kobiet. Grupę kontrolną stanowiło 20 zdrowych ochotni-
ków. Badania przeprowadzono przed oraz 4 tygodnie po zabiegu chirurgicznym.
Wyniki: Dobowe stężenia HGF przed leczeniem były znamiennie wyższe u chorych z rakiem płaskonabłonkowym jamy ustnej niż
w grupie kontrolnej (p < 0,001). Stężenie HGF we krwi istotnie zwiększyło się u chorych po resekcji guza i regionalnych węzłów chłon-
nych. Obserwowano dodatnią korelację między stężeniem HGF a wielkością guza. Nie stwierdzono istotnego związku między stężeniem
HGF a stopniem jego histologicznego zróżnicowania, nie mniej jednak obserwowano wyższe jego stężenia w przypadku raków ocenio-
nych jako G3, niż w G2 i G1.
Wnioski: Wyniki badań sugerują, że HGF może odgrywać rolę w patogenezie oraz mieć znaczenie w monitorowaniu przebiegu klinicz-
nego raka płaskonabłonkowego błony śluzowej jamy ustnej. (Endokrynol Pol 2008; 59 (6): 467–470)
Słowa kluczowe: rak płaskonabłonkowy błony śluzowej jamy ustnej, angiogeneza, HGF, TNM, skala histologicznego zróżnicowania guza
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Introduction
Oral cancer is a world health problem accounting for
some 400 000 new cases annually [1]. Squamous cell
carcinomas are the most frequent head and neck neo-
plasms and the sixth most frequent cancer in the world
[2, 3]. Clinical and pathological parameters are inade-
quate for prognostic characterisation, since patients with
equivalent tumour sites, TNM stages and histological
grades may differ widely in the course of their disease
and in survival. Treatment modalities include surgery,
radiotherapy and chemotherapy, but disease control is
limited, not least because approximately 25% of cases
develop second primaries after first intervention [4].
Generally, squamous cell carcinoma has a poor pro-
gnosis because of its tendency towards local invasion
and subsequent metastasis, which is mediated by mul-
tiple factors and angiogenesis [5]. Thus the identifica-
tion of factors related to tumour genesis may lead to
the development of novel tools to asses the malignancy
of oral squamous cell carcinoma. The role of polypepti-
de growth factors in the pathogenesis in neoplastic di-
seases is currently the subject of several investigations.
The mitogenic, differentiative, antiapoptotic and angio-
genic properties of these peptides influence the proli-
feration of many cell types, including normal and trans-
formed cells. There is evidence that tumour growth is
dependent on angiogenesis, the formation of new blo-
od vessels from pre-existing endothelium [6, 7]. Angio-
genesis is a multi-step process involved in the prolife-
ration, migration and differentiation of endothelial cells
and is controlled by a finely tuned balance of angioge-
nic inducers and inhibitors [8]. Tumour cells produce
several biologically active angiogenic factors which are
known to play a crucial role in tumour angiogenesis in
many different tumour types [9–11]. Hepatocyte growth
factor (HGF) is a potent mitogen for epithelial cells,
which regulates cell proliferation, migration, survival
tumour angiogenesis and invasiveness [12]. Originally
HGF was purified from rat serum and characterised as
a substance that stimulates the growth of hepatocytes
[13]. Currently, it is known as a pleotropic cytokine that
acts on epithelial cells in several organs [14]. Because
HGF is involved in cell proliferation, blood vessel for-
mation and invasion, it is supposed that it plays a role
in carcinogenesis and metastasis [15]. Some investiga-
tions suggest that HGF plays an important role as a
paracrine factor in the invasion and metastasis of oral
squamous cell carcinoma and an elevated serum level
of HGF can be a predictive marker for metastasis for-
mation in these patients [16].
This constitutes a preliminary report on serum le-
vels of HGF in patients with oral squamous cell carci-
noma before and after initial treatment. The research
is being continued and will be presented in the next
article.
The aim of the study presented here was to deter-
mine the serum concentrations of HGF in patients with
oral squamous cell carcinoma before and after initial
treatment.
Material and methods
The investigation was carried out before and four we-
eks after surgery in a group of 10 men and 10 women
aged between 50 and 68 years who had been hospitali-
sed at the Department of Craniomaxillofacial Surgery
because of oral squamous cell carcinoma. All patients
were staged according to the TNM classification of tu-
mours. They had not received any previous treatment.
The control group consisted of 20 healthy volunteers.
None of the patients was found to be suffering from
any infection or fever during the examinations. All had
a normal body mass index (BMI) of 19–24. Patients with
chronic diseases of the endocrine system and those with
complaints of the circulatory, respiratory and excreto-
ry systems were excluded form the study. None of the
patients received any medication during the seven days
prior to the study or during the study period itself. The
patients were treated using tumour and regional lymph
node resection. An intravenous cannula was inserted
into the ulnar vein of each of the patients studied. Blo-
od samples were collected before and four weeks after
surgery at 8.00 a.m., 2.00 p.m., 8.00 p.m. and 2.00 a.m.
The serum was frozen at –75°C until assayed. In all blo-
od serum samples the concentrations of HGF were de-
termined in the laboratory in the Department of Patho-
physiology. To measure HGF levels in serum a com-
mercially available ELISA kit was used (Quantikine
Human HGF Immunoassay; R&D System Inc). The results
obtained were subjected to statistical analysis. P < 0.05
was accepted as significant. Results in pg/ml were
expressed as the mean ± SD. The difference between
the mean values of the analysed parameters was asses-
sed using the Mann-Whitney U test or Student’s t-test
for unpaired variables. Homogeneity of variance was
checked with the Fischer test.
Results
In patients with oral squamous cell carcinoma daily
oscillations of the mean values of HGF were significan-
tly higher than those in healthy volunteers both before
and after the initial treatment (p < 0.001) (Fig. 1). Ho-
wever, serum concentrations of HGF were significan-
tly higher in those patients who had undergone tumo-
ur and regional lymph node resection. Serum HGF le-
vels correlated positively with primary tumour stage
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(Fig. 2). In our study no significant association was ob-
served between HGF levels and histological differentia-
tion, but the daily oscillation of HGF was higher in those
with G3 than in those with G2 and G1 status (Fig. 3).
Discussion
Oral squamous cell carcinoma is characterised by a high
degree of local invasion and a high rate of metastases
to the cervical lymph nodes. Furthermore, these tumo-
urs show local recurrence after initial treatment, proba-
bly because of a tendency to micro-invasion and micro-
metastasis of the tumour cells at the primary site. Tu-
mour growth and invasion involve multiple interactions
not only by tumour cells but also between tumour and
stromal cells and extracellular stroma. The process of
metastasis and invasion consists of interactions betwe-
en cancer and host cells. Several investigators have re-
Figure 1. Daily oscillations of the mean values of HGF [pg/ml] in the peripheral blood in patients with oral squamous cell carcinoma
before and after the treatment as well as in the control group
Rycina 1. Dobowe wahania średnich wartości HGF [pg/ml] we krwi obwodowej u chorych na raka płaskonabłonkowego jamy ustnej
przed i po leczeniu oraz u osób z grupy kontrolnej
Figure 2. Correlations between daily oscillations of the mean values
of HGF in the  peripheral blood and tumour stage (T) in patients
with oral squamous cell carcinoma
Rycina 2. Korelacje między dziennymi wahaniami średnich wartości
HGF we krwi obwodowej i stopniem zaawansowania guza (T)
u chorych na płaskonabłonkowego raka jamy ustnej
Figure 3. Relationships between daily oscillations of the mean values of the HGF in the peripheral blood and histological differentiation
of the tumour (G) in patients with oral squamous cell carcinoma
Rycina 3. Zależności między dobowymi wahaniami średnich wartości HGF we krwi obwodowej i histologicznym zróżnicowaniem guza
(G) u chorych na płaskonabłonkowego raka jamy ustnej
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ported that local interactions between cancer cells and
stromal cells, such as fibroblasts, lymphocytes or endo-
thelial cells, are important for regulating angiogenesis,
migration and invasion of tumour cells [17, 18]. HGF is
mainly produced by mesenchymal cells such as fibro-
blasts. In fibroblast-derived factors, such as HGF, TGF-
b, IL-1, IL-6, VEGF, b-FGF and TNF-a, hepatocyte
growth factor is the most likely candidate for affecting
the invasion and metastases of oral cancer [19]. Matsu-
moto et al. [20] reported that gingival fibroblasts enhan-
ced the invasion of oral squamous cell carcinoma in vi-
tro. In several studies a relationship between serum con-
centrations of HGF in cancer tissues and disease pro-
gression has been noted in patients with gastric, breast
and lung cancer [21–23]. This relationship has not been
reported in patients with oral squamous cell carcino-
ma. Uchida et al. [24] reported that elevated HGF levels
in cancer tissue can be a predictive marker for metasta-
sis formation in patients with oral squamous cell carci-
noma. They also examined serum levels of HGF in the-
se patients and showed significantly higher levels of
HGF than in healthy volunteers. Furthermore, they
showed that in patients who had residual tumours after
surgery the serum levels of HGF did not significantly
differ before and after treatment. No significant corre-
lations were reported between serum levels of HGF and
tumour size, lymph node metastases or the prognosis
of the patients. In our investigation high serum levels
of HGF were detected in patients with oral squamous
cell carcinoma before treatment. After initial treatment
a marked boost in serum HGF levels was observed. It is
known that growth factors at supraoptimal concentra-
tions sometimes inhibit the growth of cells [25–27]. On
monolayer culture exogenous HGF did not stimulate
cell growth but inhibited the growth at higher concen-
trations [24]. Thus it is likely that increased daily serum
activity of HGF in patients after initial treatment of oral
squamous cell carcinoma may inhibit cancer progres-
sion. We showed positive correlations between HGF
serum levels and tumour stages. On the basis of these
results, a higher preoperative serum level of HGF is
shown to be closely related to a more advanced TNM
stage. The preoperative level of HGF may thus reflect
the severity of invasive oral squamous cell carcinoma.
Chen et al. [16] also showed a significant association
between HGF and tumour size. They reported that HGF
concentrations were higher in T3 and T4 than in T1 and
T2 oral squamous cell carcinoma. In our study no signi-
ficant association was observed between HGF levels and
histological differentiation, but the daily oscillation of
HGF was higher in patients of G3 than those of G2 and
G1 status. It is generally known that a higher G status
corresponds to a poorer prognosis in oral squamous cell
carcinoma.
Conclusions
Our data showed that changes in HGF serum concen-
tration can be important pathogenic elements involved
in the progression of oral squamous cell carcinoma and
may be a useful marker for clinical monitoring.
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